OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)

Trial Profile

OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ocular inflammation
  • Focus Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 05 Dec 2016 According to an EyeGate Pharmaceuticals media release, the data from all stages of this study will form the basis for a randomized, double-masked, placebo controlled trial of iontophoretic EGP-437 in cataract surgery patients (CTP 273163).
    • 05 Dec 2016 Results published in the an EyeGate Pharmaceuticals Media Release.
    • 29 Nov 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top